Abstract 110P
Background
Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma with high metastatic propensity and is often diagnosed at advanced stages, raising public health concerns in its endemic regions such as South China and Southeast Asia. The study of NPC metastasis is hindered by the lack of appropriate models capable to recapitulate the heterogeneous tumour microenvironment in vitro. The current study aims to generate an in vitro model to represent the in vivo biology for NPC and characterize the spheroid invasion in real time.
Methods
To mimic the microenvironment encountered by NPC cells in vivo, heterotypic multicellular tumour spheroids (MCTSs) consisting of triple co-culture of NPC cells (HK-1), fibroblasts (MRC-5), and endothelial cells (HUVEC) was generated using a scaffold-based method. Through histological and immunofluorescence analyses, the morphological characteristic and the organization of the MCTSs were characterized. Tumour spheroid migration assays were conducted on the extracellular matrix (ECM). Quantitative real-time measurements of migration and invasion through an ECM barrier of the MCTSs were conducted by using a real-time cell analyser.
Results
Heterotypic MCTSs constituted from HK-1, MRC-5, and HUVEC formed irregular mass and stellate morphology structure, with loosely arranged cells observed as revealed by H&E staining. The cells demonstrated tumour features including high chromatic and pleomorphism, high nuclear-to-cytoplasmic ratio, mitosis, and necrosis. Immunofluorescence staining showed the presence of NPC cells, fibroblasts, and endothelial cells in the heterotypic MCTSs. Through real-time cell monitoring, this heterotypic MCTSs showed migration and invasion at 1:10 Matrigel with 0.5 μg/μl fibronectin.
Conclusions
The three-dimensional model generated in this study successfully reconstructed the in vivo biology of NPC. To our knowledge, this is the first report on NPC spheroid model that incoporate both tumour and stromal cells. 3D co-culture spheroid is holding a great promise as next generation standard of in vitro pre-clinical model for biomarkers discovery, accelerating drug screening process, and achieving a more precise personalized treatment for cancer patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Fundamental Research Grant Scheme FRGS (FGRS/1/2020/SKK0/UCSI/02/2) by Ministry of Higher Education (MOHE) Malaysia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract